Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Cancer J. 2022 May-Jun;28(3):208–223. doi: 10.1097/PPO.0000000000000591

Figure 11.

Figure 11

Mortality outcomes during the Women’s Health Initiative trials of hormone replacement therapy for women aged 50–59 years (y) at the time of randomization (28). Magnitude of mortality reductions was similar across both Women’s Health Intervention trials of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate (CEE plus MPA) and conjugated equine estrogen alone (CEE). For the CEE plus MPA trial, median intervention was 5.6 years [interquartile range, 4.9–6.5 years]. For the CEE alone trial, median intervention was 7.2 years [interquartile range, 6.5–8.2 years]. For the pooled trials (CEE plus MPA and CEE alone) median intervention was 6.3 years [interquartile range, 5.3–7.3 years]. HR = hazard ratio; No. = number; CI = confidence interval